Takashi Masuko

10PUBLICATIONS
30CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene and molecular therapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 06, 2025
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb.

Takashi Nakano, Kouki Okita, Shogo Okazaki

|Feb 22, 2023
CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2/CD98 antibody inhibits the growth signal of human breast cancer cells.

Akitaka Yamasaki, Kumiko Maruyama-Takahashi, Kento Nishida

|Feb 08, 2023
Dual-targeting therapy against HER3/MET in human colorectal cancers.

Akitaka Yamasaki, Rikuto Miyake, Yuta Hara

|May 28, 2022
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized <sup>64</sup>Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.

Fukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto

|Feb 16, 2022
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.

Kana Hasegawa, Shunya Ikeda, Moto Yaga

|Nov 19, 2020
Antitumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene.

Kouki Okita, Yuta Hara, Hiroshi Okura

Pageof 2

Frequent Collaborators

1 joint publications

Hideki Nakayama

1 joint publications

Osamu Nagano

1 joint publications

Reiko Sugiura

1 joint publications

Hiromitsu Komiyama